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INTRODUCTION
General Introduction
The problem discussed in this Thesis is in general
that of the removal of a metabolic end product from the
body, once one of the excretory routes normally open to
that substance is in part or totally blocked by an enzyme
inhibitor.

In more specific terms, that product is carbon

dioxide, the end metabolite of internal respiration.

The

hampered excretory route is that of the carbonic anhydrasecatalyzed bicarbonate-carbon dioxide carriage system.

In

this Thesis, the effects of partial in vivo inhibition of
carbonic anhydrase by the powerful enzyme inhibitor acetazoleamide (Diamox) are reported.
The effects of acetazoleamide administration upon
renal excretion of fluids and electrolytes has been well
studied, and the remarkable alkaline diuresis produced by
administration of this agent in edematous states is well
known.

Similarly, the action of the drug in other organ

systems has been investigated to greater or lesser extent.
Less well understood are the effects of carbonic anhy
drase inhibition upon carbon dioxide exchange as it is seen
at the lung.

From a consideration of the reaction

1

2
catalyzed by carbonic anhydrase at or below pH 7.5,
C.A.
HCCf
H CO ~
3 ^
2 3 ^ 0 • A . " C°2 ^ H2°

(1)

it would seem that carbon dioxide evolution at the lung
would be diminished should the enzyme be inhibited.

This

should result in at least a temporary alteration in the
acid-base status of the body if adequate blood levels of
the drug were obtained.

It was felt that additional stud

ies were indicated to see if this alteration could be meas
ured in humans as it eventuated in changes in ventilation
and alveolar gas exchange as measured by standard tech
niques.

It is the purpose of the present investigation to

study the effects of acetazoleamide administration on sev
eral such parameters in normal human subjects.
Biological Behavior of Carbon Dioxide
In a work such as this, a brief consideration of the
chemical characteristics of carbon dioxide will be helpful
in understanding its reactions in a complex system such as
highly buffered human blood.
In this case, the reactions of carbon dioxide are
those in an aqueous solution, wherein about one per cent of
the dissolved carbon dioxide exists as the dibasic acid.
carbonic acid.

The process whereby carbon dioxide is

3
hydrated to carbonic acid is one involving a rearrangement
of valence bonds and tahes a small, but readily measurable
time.

Although this reaction is enzyme catalyzed in the

body, it still proceeds at an appreciable rate in the ab
sence of the enzyme.

The temperature coefficient of the

hydration reaction is considerable, and reaction (1) pro
ceeds only slightly to the left in water and most other
aqueous solutions at body temperature.

That the situation

was different in cases where effective hydrogen-ion buffers
existed, e.g., in mammalian blood, was recognized as early
as 1935 by Houghton.81

The complex physical and enzyme

chemistry of the hydration reaction has been discussed in
the literature, and physical constants for the reaction
have been determined.81'^8,82'88
The dehydration reaction, i.e «, that to the right in
equation (1), is of greater pertinence to the present
issue .

The kinetics of this reaction and physical con-

stants describing it have also been determined and reported. 31,33,80,83

At all temperatures studied, the veloc-

ity constant of the dehydration reaction is greater than
that of the hydration reaction, when correction for buffer
action is made.

4
Carbon Dioxide Transport in the Blood
The transport of carbon dioxide in the blood has in
terested both physiologists and biochemists since the turn
of the century.

Early workers in this field included Pem-

brey, ^ Houghton,Christiansen et al, ^ Henriques,^ and
others.

In 192 5, Hartridge and Houghton^ showed that the

speed of the hydration-dehydration reaction in aqueous so
lutions was far too slow to keep pace with the observed
rate at which carbon dioxide was expelled at the lungs or
taken up in the tissues by the circulating blood.

After

considerable preliminary investigation. 30,111 Brinkman and
Margaria1^ found that the hydration of carbon dioxide was
markedly accelerated by the addition of 1:20,000 solutions
of hemoglobin.

This acceleration was not accompanied by a

change in the equilibrium point, and hence the presence of
a catalyst was assumed.

This was affirmed by the separa-

tion of such a catalyst from the hemoglobin of ox red blood
cells by Meldrum and Houghton^ in 1932.

P. G. Eggleton

was credited with naming the new enzyme “carbonic anhydrase“ the following year.
By 1934 a considerable body of knowledge had accumu
lated regarding carbon dioxide transport by the blood and

5
Roughton8^ was able to postulate a scheme much like that
held today (see Figure 1).

This scheme will be discussed

in more detail later.

PLASMA

RBC
6%

ALVEOLAR GAS

5%

H HbCOj

■> COg I

*

FROM:
HzCOj

HCOj

65%

H Hb COj 27%
C02

8%

HCOj

. 89%

C02 EXCHANGE IN THE LUNGS

Figure 1. Schematic Summary of Main Processes
Which Occur Within the Blood, During Output of
Carbon Dioxide and Uptake of Oxygen at the
Lung.
Isolation, Purification, and Chemical Properties
of Carbonic Anhydrase
Considerable effort was expended in determining the
chemical properties and characteristics of carbonic anhy
drase.

Keilin and Mann48 found a strong correlation
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between the zinc content and the carbonic anhydrase activ
ity of their preparations, a fact which was promptly confirmed by Scott and Fisher, 90,106 who obtained amorphous
preparations of higher activity but lower metal content.
i.e • # 0,20% rather than Keilin and Mann's 0.33%.

Recent

studies have demonstrated that the metal is not required in
the diet for adequate enzyme synthesis,but that altered .
blood levels of the metal do occur in disease states. 108
Recent values for the zinc content of whole blood are;
8.8±2.Q micrograms/cc? for packed red blood cells, 14.4±2.7
micrograms/cc; and for plasma, 3.Oil.6 micrograms/cc.
There was no significant variation in zinc levels due to
age or sex. 107
Petermann and Hakala71 examined the preparations of
Scott and Fisher with the ultracentrifuge and assigned a
molecular weight of 30,000 to the enzyme, which indicates
a size small enough to pass the intact glomerular membrane.
Its renal clearance is less than four per cent that of cre
atinine, and it disappears rapidly from the glomerular fil
trate with decreasing plasma concentrations.26
The isoelectric point of the enzyme is between pH 5.3
and 5.6.50'

It is not easily salted out of red cell
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extractions, concentrations of greater than 85% ammonium
sulfate being necessary to precipitate it.

This allows for

the differential precipitation of protein contaminants with
increasing concentrations of ammonium sulfate.
Scott’s amino acid analysis of the enzyme established
the nitrogen content as 15.9%, the cystine as 1.3%, and the
tyrosine as 4.1%.

Both Millon’s test and the xanthoproteic

reaction for aromatic amino acids are strongly positive.
Other tests for protein, though positive, are less markedly
so.

Tests such as the Molish and nitroprusside reaction

are faintly positive, but this may be due to impurities.
Dried preparations of crude enzyme seem to keep in
definitely without losing activity.

Solutions suffer rapid

inactivation unless refrigerated; stability of the enzyme
decreases with increasing purity of the preparation.

Most

preparations of carbonic anhydrase are stable in buffer so
lutions over a range of pH 4.0-11.0 for at least 30 minutes.

Exposure to acid solutions below pH 3.0 or to alka-

line solutions above pH 13.0 for this length of time result
in inactivation of the enzyme.

Carbonic anhydrase is also

unstable at high temperatures, being completely destroyed
after 30 minutes of exposure to temperatures in excess of
00—(55^ 0 109
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Kinetics of the Carbonic Anhydrasa-Catalyzed System
Houghton and Booth^ found that the rate of the
enzyme-catalyzed reaction (1) varied with the substrate
concentration in the manner described by the Michaelis
equation.

Values for the physical constants involved in

the enzyme chemistry of carbonic anhydrase are available
in the literature

^

Using various buffers at low concentrations (0.010.03 M), and a crude chloroform red blood cell extract,
Houghton and Booth^^ were able to describe a relationship
between pH and enzyme activity.

Although the critical

parts of the activity-vs.-pH curve below pH 6.0 and above
pH 9.0 require confirmation,^ the dissociation constant of
the enzyme-substrate complex appears to be minimal at about
pH 6.5, increasing in linear fashion with increasing alka
linity up to about pH 10.0, where the value is about five
times greater than at pH 6.5.

The argument that pH optima

are dependent on buffer systems used has been fairly well
discarded in the case of carbonic anhydrase since buffers
affect the reaction even in the absence of the enzyme, and
in current work duplicate results have been achieved using
entirely different buffers. 109

9

The system catalyzed by carbonic anhydrase is highly
temperature sensitive.

Roughton79 gives a Q^q of 1.4 (the

rate of the enzymic reaction increases 1.4-fold per 10° C
rise) in his most recent analysis.
tion has a Q^q of 2.9.

The uncatalyzed reac

In 1949, Altschule and Lewis^ at

tempted to evaluate the activity of carbonic anhydrase at
body tempe ra tu re, i.e * # 37° C, and pH 6.90, using the
method of Mitchell.66

However, this research was performed

using a nonphysiologic pH range and in the presence of
ionic constituents not completely duplicating the electro
lytic milieu of the red blood cell in vivo.
Over the years many methods have been employed to
study the kinetics of reaction (1) in the presence of car
bonic anhydrase.

Among them have been procedures involving

the use of electrodes, studies measuring changes in elec
trical conductivity, thermal evaluations in the rapid-flow
apparatus,85 and recently, the use of aerotonometers.88
All these methods have met with limited success and at
present only the boat-manometric method of Brinkman et al,
(see references in Van Goor189), and the changing-pH method
of Philpot and Philpot72 are in much use.

These methods

have been discussed and criticized in the literature by
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several authors.14'20'^'86

A modification of the Philpot

method was used in the present work as a basis for deter
mining the concentration of acetazoleamide in red cells and
plasma.

This method is based on the amount of inhibition

produced by the drug on the normal catalytic rate of reac
tion (1)

(see appendix)•

Distribution of Carbonic Anhydrase in Tissues
Other Than Blood
In vertebrates, carbonic anhydrase occurs in greatest
amounts in the red blood cell, but very significant amounts
are also present in the kidney,28 ciliary body. 109 and gas
tric mucosa.27

Smaller amounts are present in the pan

creas,48'110 salivary glands,12 most parts of the central
nervous system,8 liver,4 testis, spleen, red muscle, and
intestinal mucosa.

It may occur in traces in striated and

cardiac muscle, the choroid and retina of the eye. 109 and
in the adrenal glands, though conclusive proof of its existence in this latter group of organs is lacking. 109
enzyme is absent from normal plasma and urine.02

The

Sobotka

et al84 have compiled an extensive review of the inverte
brate distribution of carbonic anhydrase.
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Consideration of the functions of carbonic anhydrase
in the red blood cell, renal cortex, and central nervous
system will be reserved for the Discussion.
With respect to the function of the enzyme in the gas
tric mucosa, Berliner et al12 has pointed out that the na
ture of its function in this location is probably that of
maintaining a normal intracellular pH in the face of active
outward extrusion of hydrogen ion and inward release of
bicarbonate, a function which cannot be divorced from gas
tric acid secretion.
In the pancreas, it seems most likely that at least
the bicarbonate of secretin-stimulated secretion is formed
in the acinar cells from blood-borne carbon dioxide.

It is

possible that a bidirectional flow of ions exists between
sodium and hydrogen ions in this location and in this con
nection, it is most probable that carbonic anhydrase func
tions here in a manner somewhat analagous to that in the
stomach. ^
In the ciliary body, carbonic anhydrase is associated
with the maintenance of high bicarbonate and carbon dioxide
concentrations in the aqueous humor, another instance of
the enzyme's being associated with the performance of acidbase work.^
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Variations of Carbonic Anhydrase Concentrations
in Health and Disease
In 1938, Houghton and BoothS3 showed that the amount
of enzyme present in the blood of goat fetuses was on the
average less than one per cent of that present in the
mother’s blood, and that the concentration did not rise
until near term.

In humans, Stevenson5^ later showed that

the newborn infant possessed less than one-half, and the
premature infant less than one-fourth of the enzyme present
in adult whole blood.
Hodgson43 found no close correlation between erythro
cytic carbonic anhydrase content and hematocrit, nor could
he demonstrate any diurnal variation in enzyme levels.

The

former concept has more recently been shown to be untrue,
i.e • * the amount of enzyme per milliliter of red blood
cells decreases with increasing hematocrit.

A continuing

increase in enzyme concentration with age into adolescence
has also been demonstrated.92
Stevenson" noted that whole blood transfusions pro
duced an instantaneous and permanent rise in enzyme levels
in infants and that transfusions of adult human plasma were
without effect in this regard.

Infants in his series who
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exhibited unexplained cyanosis showed lower levels of car
bonic anhydrase, but he did not feel that the two were etiologically related.
Our knowledge of the carbonic anhydrase content of
blood in pathological states is fragmentary.

Enzyme levels

have been studied in the anemias. 108 jaundice, congestive
heart failure, asthma, Addison1s disease, the leukemias.
carcinoma, and tuberculosis, all with equivocal results
(see references in Van Goor 109 ).

Recently, Shepard^2 has

shown that there was no significant increase in red blood
cell carbonic anhydrase activity in patients with chronic
obstructive respiratory disease and marked carbon dioxide
retention.
Inhibitors of Carbonic Anhydrase
Other Than Acetazoleamide
The activity of carbonic anhydrase is partially or
completely inhibited by a number of substances.

Many of

these are unspecific and also inhibit other catalytic sys
tems such as catalase, peroxidase, and cytochrome oxidase.
Among these substances are the cyanides, carbon monoxide.
azides, sulfides, and the metallic salts of copper, silver.
gold, and mercury.

The effect of metallic zinc salts is
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questionable.

The salts of these heavy metals probably

exert their effect as protein precipitants.

The azides,

cyanides, and sulfides, in concentrations ranging from 10""4
to 1Q~5 M, almost certainly exert their effect directly on
the active center of the enzyme.

Saturated solutions of

phenylurethan produce marked inhibition of the enzyme.3^
Dilute solutions of chloride, bromide, and nitrates are
also mildly inhibitory.1^
Kiese and Hastings^0 found that the oxidizing agents
iodide and potassium permanganate produced marked inhibi
tion of the enzyme in concentrations similar to that in
which the azides, etc • I were effective.

The inhibition

produced by these oxidizing agents was reversed by ascorbic
acid or cystein when the contact between oxidizing agent
and enzyme had not exceeded ten minutes.

Carbonic anhy-

drase was not inhibited by oxygen tensions up to seven at
mospheres pressure.^7
The salts of sodium, potassium, magnesium, calcium.
aluminum, tin, chromium, manganese, ferrous and ferric
iron, and cobalt do not inhibit the enzyme. 109
Repeated references in the literature 10,95 regarding
the ability of prontosil and sulfanilamide to lower the
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carbon dioxide combining power of the blood led Mann and
Keilin5^ to suspect that these compounds might have an in
hibitory effect on carbonic anhydrase.

That this was the

case was quickly proven when gastric mucosa, solutions of
laked blood cells, and dilute pure solutions of the enzyme
were subjected to the drug.

These workers demonstrated

that derivatives of sulfanilamide, unsubstituted on the
-SO2NH2 nitrogen group, were inhibitory at concentrations
as low as 2.0 x 10 0

M.

They found that the sulfonamide

group itself was directly concerned with the effect, since
substitution of even one of the hydrogen ions of the amido
group resulted in a loss of activity.

Sulfanilamide deriv

atives were without effect on catalase, peroxidase, cyto
chrome oxidase, and other enzymes.

This work was confirmed

by Locke and his coworkers.53
Davenport28 subsequently showed that the poisoning ac
tion of sulfanilamide was much less in concentrated than in
dilute solutions of the enzyme.

He later suggested a mole-

to-raole inhibition of the enzyme resulting from the forma
tion of an enzyme-inhibitor complex.
Other workers have demonstrated that high degrees of
inhibition could be achieved with other sulfanilamides^^
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and with prontosil and neoprontosil,63 which latter sub
stances are metabolized to the less active form of sulfanilamide in vivo.

Keilin and Mann^3 extended their work

to whole red blood cell suspensions and demonstrated that
in this situation, if less than 97% of the enzyme is in
hibited by sulfanilamide, the catalyzed reaction is en
tirely unaffected.

In order to reduce the catalyzed re

action rate by 50%, more than 99,5% of the enzyme must be
inhibited, and for 90% rate depression, more than 99.8% of
the enzyme must be inhibited.
Acetazoleamide, A Potent Carbonic Anhydrase Inhibitor
In 1948, Krebs153* pointed out that substitutions on the
N4 (amino) nitrogen greatly enhanced the activity of sulfa
nilamide, and shortly thereafter, Roblin and Clapp77 syn
thesized acetazoleamide (DiamoxR), an agent having inhibi
tory activity several hundred times that of sulfanilamide
in vitro.

The drug produced 50% inhibition of the enzyme

at 0° C with concentrations on the order of lO”8 M.
The chemical formula of this agent appears in Figure 2:
H

N — N
u
H
-c-n-c-c
l

ch3

II

o

\

s

/

O
H

s - nh2
i,
o

Figure 2. Structure of Acetazoleamide (DiamoxR,
6063), 2-acetylamino-1,3,4-thiadiazole-5-sulfonamide.
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Milne65 has pointed out that the spatial arrangement
of the molecule is very similar to that of carbonic acid,
the normal substrate for carbonic anhydrase (see Figure 3).

L
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i

Figure 3. A Diagrammatic Representation of the
Structure of (a) Carbonic Acid, and (b) a Car
bonic Anhydrase Inhibitor Such as Acetazoleamide.
From Milne*65
This agent has a molecular weight of 222, is readily
absorbed orally, and suffers little from in vivo destruc
tion*44

It is a white crystalline solid which melts at

approximately 258° C, and is weakly acidic, pKa=7*2.
is frequently used in the form of its sodium salt.

It
Acet

azoleamide itself probably undergoes only minor in vivo
alteration, but Maren55 has reported the dealkylation of
a related compound to an agent either closely resembling.
or actually being acetazoleamide itself.
In doses of 20 rag/kg and less, the drug seems to be
completely absorbed from the alimentary canal within two
hours.

With oral administration, higher drug concentra

tions are seen in the red cell than in the plasma
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regardless of the size or time course of the dose.

These

levels maintain themselves longer and at a higher level
than do the plasma concentrations of acetazoleamide.

The

reverse obtains when the drug is administered intravenously.
Over 80% of the administered dose is excreted unchanged in
the urine at the end of 24 hours in dog and man; it is pre
sumably filtered through the glomeruli and reabsorbed by
the tubules.
The toxicity of the drug was very low in all species
studied by Maren et al.^

Prolonged administration of

500-1000 mg/kg/day for 1-2 weeks in animals resulted in
weakness, anorexia, and vomiting and was presumably inci
dent to the severe electrolyte imbalance (particularly the
sodium and potassium loss) produced by the drug in such
large amounts.

The nausea, parasthesias, drowsiness, and

headache which accompany acetazoleamide administration in
man will be mentioned elsewhere in this Thesis.

Isolated

cases of agranulocytosis and one of thrombocytopenic pur
pura have also been reported.^5
Acetazoleamide has been used clinically in the treatment of glaucoma,86 hydrocephalus, 13, 58 peptic ulcer. 103
and epilepsy88

In all but peptic ulcer therapy, admin

istration of the drug has met with considerable success.
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Urinary acidification, as accomplished by the normal
kidney is an important part of the blood buffer and respir
atory mechanisms which constitute the body's line of de
fense against acid-base imbalance.

Carbonic anhydrase was

first demonstrated in bloodless kidney homogenates in 1941
by Davenport and Wilhelmi.^9

The enzyme is now thought of

as the chief agent responsible for tubular bicarbonate re
absorption in the kidney.

Most recent data indicate that

it is a supportive, but not obligatory component of the
total urinary acidification mechanism.12'^4
In the kidney, acetazoleamide administration results
in diminished tubular secretion of hydrogen ion, which
eventuates in increased excretion of bicarbonate, sodium
and potassium ions, and water.^

The diuretic effect of

the drug is largely dependent upon the osmotic action exerted by the augmented excretion of bicarbonate.

In mod-

erate to mild cases of congestive heart failure, several
workers have shown the drug to be fairly effective as a
diuretic when taken orally.

This is especially true early

in the course of treatment when serum bicarbonate levels
are high; because of this self-limiting effect, it is prob
ably better to use the agent as an adjuvant to mercurial
therapy.38'60
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Effects of Carbonic Anhydrase Inhibition
on Ventilation and Carbon Dioxide Transport
Interest in this area began in 1940 when Beckman et
al10 studied the effects of sulfanilamide on acid-base me
tabolism.

These workers found a hyperpnea in humans two

and one-half hours after moderate oral sulfanilamide admin
istration.

This was preceded by a fall in serum pH and bi

carbonate.

Though the hyperpnea was a relatively late

event, they found a considerably earlier reduction in the
alveolar PCO2, a phenomenon for which they could not ac
count.

They concluded that Mthe hyperpnea following sulfa

nilamide . . . might be regarded as a secondary event com
pensatory to plasma bicarbonate reduction caused by re
moval of fixed base in the urine."
That carbon dioxide excretion relative to ventilation
might be decreased was shown the following year (1941) by
Roughton et al87 at the Harvard Fatigue Laboratory.

He

demonstrated that after exhaustive treadmill exercise fol
lowing sulfanilamide, carbon dioxide output was definitely
decreased in the face of constant or increased minute volumes.

These workers were the first to allude to the possi-

bility of a decrease in the alveolar/arterial (A/a) pC02
ratio following carbonic anhydrase inhibition.

They also
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suggested the now generally accepted hypothesis (see Dis
cussion) that an increased load is placed upon the
carbamino-hemog1obin transport mechanism when the carbonic
anhydrase system is inhibited.
In 1953, Becker et. al9 presented a report in which
50 mg/kg of acetazoleamide had been given orally to a few
human subjects.

Although no blood drug levels were meas

ured, observations made 1

2 hours later indicated no

change in minute volume, respiratory quotient, or arterial
or alveolar carbon dioxide tension while breathing air.
Observations made during mild exercise sufficient to double
the oxygen consumption did not appear to reveal any impair
ment in carbon dioxide elimination.

A strong alkaline di

uresis had been observed in these subjects during the pe
riod of the experiment.
Tomashefski et al 105 in that same year and in the year
following 104 had been able to demonstrate a somewhat different picture.

In two humans treated with 25 mg/kg

orally, these workers noted only a small and probably in
significant drop in minute volume and carbon dioxide out
put, prior to a return within one and one-half hours to
normal values.

However, they found that intravenous doses
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of from 5-100 mg/kg produced an increase in minute volume
and a sharp drop in alveolar PCO2 in anesthetized dogs.

In

these animals the arterial PCO2 rose only slightly, but
when the animals were breathed with 15.58% oxygen in nitro
gen, the arterial pC(>2 rose sharply above untreated con
trols.

In both the air-breathing and low oxygen-breathing

dogs, the arterial pH dropped rapidly following 100 mg/kg
of intravenous acetazoleamide.

The effects were maximal

within approximately 90 minutes.

No blood drug levels were

determined, but the authors concluded that these data ’’were
consistent with an impairment of carbon dioxide transport
from blood to alveoli.'*
Shepard and his coworkers91 studied two subjects who
had ingested about 15 mg/kg of acetazoleamide (500 mg the
day prior to, and 750 mg the day of the study).

They found

that with severe treadmill exercise following this dosage
schedule, they were able to obtain arterial-alveolar (a-A)
pCC>2 differences from 5-12 mm Hg.

The respiratory quotient

in these subjects was 0.85 during the experimental period.
suggesting to these workers that the metabolic production
of carbon dioxide exceeded carbon dioxide output at the
lung under such conditions.

These results were in support
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of the earlier work of Roughton and his group®^ at the
Harvard Fatigue Laboratory.
In 1958, Carter and Clark18 extended the work of Tomashefski et al.1^'18^

These workers, using unanesthetized

dogs, were not able to demonstrate any decrease in carbon
dioxide output with 99% inhibition of the enzyme but postu
lated that such must occur.

These workers produced a sec

ond paper17 which reported that the administration of
100 mg/kg of intravenous acetazoleamide to unanesthetized
dogs increased the tolerance of these animals to artifici
ally produced high-altitude hypoxia.

They noted an in

crease in ventilation and alveolar and arterial p02/ an in
crease in arterial pC02, and a decrease in alveolar pC02
over nontreated controls at the same “altitude11.
Table I)

(See

They suggested that this combination of events

and the drug-induced, accelerated renal excretion of cati
ons would be beneficial to persons undergoing rapid accli
matization to high altitudes.
Dogs at 20,000 feet (6100 M)

Minute Volume
Alveolar pC02
Arterial pC02
Arterial p02

(L/min)
(ram Hg)
(mm Hg)
(mm Hg)

Control

Acetazoleamide

3.13
22.1
29.0
32.8

4.72
14.9
34.8
42.6

Table I. From Carter and Clark.17 Effects of
Acetazoleamide on Unanesthetized Dogs at High
“Altitudes'1.
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Lawson5^ had earlier noted similar effects in rabbits
treated with sulfanilamide as had Toma she f ski et al1134'105
using acetazoleamide.
In a paper which appeared in 1958, Pocidalo et al74
presented more indirect support for the early drop in car
bon dioxide output referred to previously by others.

In

anesthetized dogs, the carbon dioxide output was seen to
drop sharply by about 20% in animals 4-8 minutes after they
had received 10-50 mg/kg of intravenous acetazoleamide*
Return to normal gas excretion did not occur in these arti
ficially breathed animals for three hours*

Little change

was seen in the oxygen uptake and changes in the respira
tory quotient paralleled changes in carbon dioxide output.
i*e *» dropped sharply initially.

Amiel et al3 confirmed

this work and demonstrated an arterial-alveolar (a-A) pC02
gradient of 17.7 ram Hg 40 minutes after the administration
of 10-15 mg/kg of intravenous acetazoleamide in similarly
anesthetized and pumped dogs.

The gradient returned to

normal some five hours after this injection.

No blood

drug levels were reported.
In the past year (1959) several papers have appeared
dealing with this subject.

Collier,21 using artificially
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ventilated, anesthetized dogs, was able to relate depres
sion of the Alveoiar/arterial pC02 ratio (A/a ratio) to red
blood cell acetazoleamide concentration.

The erythrocytic

drug concentration producing maximal effects (A/a pC02 ra
tios in the range of approximately 0,5) ranged from 20-30
micrograms/cc (9-13 x 10~5 M),

Higher concentrations of

the drug had no greater effect.
Mithoefer^7 demonstrated in dogs an immediate fall in
carbon dioxide output relative to ventilation when carbonic
anhydrase was 96% inhibited by 20 mg/kg of intravenous
acetazoleamide.

He noted a 2.5-fold increase in minute

ventilation 30 minutes after this dose, which dropped to
1.5-fold in 1% hours.

During this period carbon dioxide

output was increased, but not to the same extent as when
the animal was artificially ventilated at the same minute
volumes as were produced in response to acetazoleamide.
If changes in R.Q. were solely due to hyperventilation.
i .e • # to an initial increase in carbon dioxide output over
oxygen consumption, he argued, one would expect an initial
increase in the R.Q. value.

That this is not the case.

even in the face of the severest drug-induced hyperventi
lation, was shown by Mithoefer's paper.
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duration,

the reaction time of the noninhibited carriage

system was only one-tenth that long88

In addition, it

is important to recall that the total system supported by
carbonic anhydrase is not entirely enzyme dependent, i*e • #
when one route of carbon dioxide excretion is blocked.
other routes are opened by a complex series of physiochemical alterations.

In summary, was the failure of early

investigators to observe these phenomena due to insuffi
cient dosage or discontinuous monitoring?
2.

Where the effects of sulfanilamide and acetasole-

amide at rest were equivocal, more positive results seemed
to be obtained during exercise,87*91

Were these effects

due in part to an increased load on the carbon dioxide car
riage system?
3.

The idea17'that any incapacity of the blood to

liberate carbon dioxide at the lungs would result in a
situation favorable to an increase in alveolar and arterial
oxygen tensions and to the unloading of oxygen at the tis
sues appealed to us as the basis for a possible new use for
acetazoleamide.

Could the agent be used as a rapid Malti-

tude acclimatizer1'?
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4.

Our knowledge of pharmacology and enzyme chemistry

includes an understanding of the importance of doseresponse relationships.

Was the disparity of much of the

foregoing data in part due to failure to take this concept
into account?

Could the work of Collier21 be repeated in

humans and used in clarification of this problem?

Could

the arterial-alveolar pCC>2 differences which Shepard^1 ob
tained with low dosages and exercise be obtained at rest.
with higher doses?

METHODS AND PROCEDURE
Ae

Low Dosage Oral Studies
In the low dosage oral studies, the subjects were

seated before a Collins Chain-Compensated Spirometer (Gas
ometer) , the running times of which were recorded by a
stopwatch,

A Liston-Becker infrared carbon dioxide ana

lyzer was attached to the airway by a penetrating 20-gauge
needle at a point two inches from the subject's mouth.
This instrument, which was used for alveolar and expired
carbon dioxide tension analysis, was connected in turn to
a Texas Rectiwriter, a recording instrument which allowed
the continuous recording of the tension trace.

The four

calibration gases for this instrument ranged from 2-8% carbon dioxide in air.

Gas removed from the circuit by the

analyzer pump was returned to the spirometer via a second
20-gauge needle inserted into the rubber airway tubing
proximal to the spirometer inlet.

A photograph of this

apparatus appears in Figure 4.
The test gas mixtures breathed were, in order:

room

air; 10% oxygen in air; 2%, and finally 4% carbon dioxide
in air.

The commercial analysis of these mixtures was

tested to the nearest 0.02% in the Scholander apparatus.
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These test gases were humidified in a water chamber before
inhalation by the subject.
In the control period, the subject breathed each of
the four mixtures in sequence.

A period of five minutes

rest period was allowed between each run, and a five-minute
equilibration period was allowed on each new gas before the
subject was "turned in” to the spirometer.

Similarly, a

fifteen minute adjustment period was allowed before the
base-line air tracing was recorded at the beginning of the
whole experiment.
After establishing base-line ventilation data for each
of the four mixtures, 10 mg/kg of acetazoleamide was ad
ministered orally.

In several cases, continuous monitoring

of the one-hour "induction period" was performed, with the
subject breathing room air.

This amount of time was shown

to be adequate for the drug to reach peak blood levels by
means of the acetazoleamide analysis we have described
elsewhere.

At the end of this one-hour period, the four-

gas protocol was repeated.
At the end of each experimental period a sample of the
collected expired gas was removed from the spirometer and
stored in one of eight mercury-filled gas tonometers.
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These samples were later analyzed for expired carbon diox
ide and oxygen tensions by means of the micro-sample gas
analyzer described and perfected by Scholander.36

In other

instances, this same data was obtained by employing the
Severinghaus CO2 electrode.
Venipunctures were performed in subjects where blood
samples were required for acetazoleamide analysis by the
method of Maren et al5^ which is described in detail in the
Appendix of this Thesis.
In several subjects an attempt was made to correlate
mixed venous pC02 with alveolar ventilation.

This parame-

ter was determined by the rebreathing method of Collier, *
in which the infrared carbon dioxide analyzer is employed
to obtain an equilibrium tension between a rebreathing bag
filled with 8-10% carbon dioxide in air and the subject's
lungs.
Data obtained from the spirometer tracings, alveolar
gas recording, and the Scholander apparatus allowed us to
construct a complete ventilation profile for each gas be
fore and after administration of acetazoleamide.

C--1
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B.

High (Intravenous) Dosage Studies
The next aspect of this study dealt with the effects

of carbonic anhydrase inhibition following intravenous
acetazoleamide administration in considerably larger doses
(to 50 mg/kg).

For this purpose, we were provided with

parenteral acetazoleamide (DiamoxR, sodium) by the Lederle
Laboratories,
In all subjects, a base-line rebreathing test was per
formed prior to the placement of an indwelling Cournand
arterial needle.

Normal values in this test virtually as

sured no ventilation-perfusion abnormalities in the subNo less than 40 mg/kg of parenteral acet-

jects tested.

azoleamide was administered to any subject.
In all but the first subject, in which data was ob
tained in the sitting position, base-line data were ob
tained in the supine position.

Ventilatory parameters were

determined as before, using the standard techniques of
spirometry.

Blood was withdrawn from the arterial needle

at intervals and analyzed for pH, pC02, and acetazolearaide
concentration.

Carbon dioxide tensions were determined by

the Severinghaus electrode and checked on the Van Slyke
apparatus.

pH determinations were performed on a Cambridge
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apparatus and expired oxygen tensions were calculated with
data obtained from an oxygen electrode.
determinations were performed as before.
tidal) peek's were measured as before.

Acetazoleamide
Alveolar (endIn these studies.

expired carbon dioxide tensions were also measured with the
infrared device, by means of sampling from a two-liter mix
ing bottle interposed in the apparatus midway between the
mouthpiece and the spirometer.
The Alveolar/arterial PCO2 ratio was calculated for
each experimental state ass
A/a

*

Alveolar PCO2
arterial pC02

(2)

Since different drug administration schedules and ex
perimental protocols were followed in each subject, each
will be discussed individually.
1.

In the first subject, CRC, the purpose of the ex-

periment was to study alterations in the A/a pC02 ratio and
ventilation both at rest and during exercise, after a
single 50 mg/kg dose of parenteral acetazoleamide.

Air

breathing controls were run for twenty minutes with the
subject in the sitting position.

Following this, fifteen

minutes of exercise was performed at 3.5 mph on a treadmill
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inclined to a 10.2% grade.

Similar parameters were meas

ured by standard spirometric technique and arterial samples
were withdrawn for the determinations mentioned above.

At

the close of this period, the subject was allowed to re
equilibrate breathing room air at rest for 30 minutes, at
which time a second base-line, or control test run was
made.
4000 mg (50 mg/kg) of parenteral acetazoleamide in
sterile saline was then injected through an indwelling in
travenous needle kept open by a slow drip of isotonic
saline.

This injection was accomplished within four min

utes, during which time the subject's alveolar pC02 and
minute ventilation were carefully monitored.

Such monitor

ing was continued for approximately 25 minutes, at which
time the exercise experiment was again undertaken.

The

subject was unable to tolerate this procedure and accord
ingly the experiment was concluded after only three minutes
of exercise.
2.

In the second subject, RMO, the exercise test was

omitted and the only studies performed were done at rest.
The dosage schedule was altered so that acetazoleamide was
given in increments to total 10 mg/kg, 25 mg/kg, 40 mg/kg.
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and 50 mg/kg (or, in terms of the total incurred dosage:
906, 2266, 3625, and 4531 mg).

Two control periods were

analyzed over a 45-minute equilibration period after the
placement of the arterial needle.

Approximately 16-18

minutes separated each graded dose, and from the time of
the first injection to the time when the total dose of
50 mg/kg had been given, 50 minutes had elapsed.

After

each injection, ventilatory and blood gas parameters were
monitored as before.
3.

In the third subject, CB, acetazoleamide was given

in doses to total 25 mg/kg and 45 rag/kg (a total dosage of
2941 mg) .

Approximately 20 minutes elapsed between the

first injection (of 25 mg/kg) and the second (to make a
total injection of 45 mg/kg).

Monitoring was similar to

that used above.
4.

In the last two subjects, BA and GB, the procedure

outlined in section 1 (subject CRC) was followed but with
the exercise test omitted.

The acute effects of 50 mg/kg

were followed for two and one-half hours to establish the
effect of steadily decreasing red cell and plasma drug
concentrations on the A/a pC02 ratio and other parameters.

RESULTS
A.

Low Dosage (10 mg/kg) Studies
Of the ten studies in this series, two are not in

cluded in this presentations

one because of obvious corti

cal control of breathing by the subject evidenced by ex
ceptionally low alveolar PCO2 values while breathing the
carbon dioxide mixtures; the other due to contamination of
the expired gas samples in the tonometers, which rendered
important parts of the analysis impossible.

The 10% oxygen

and 2% carbon dioxide studies were performed in only five
subjects.
1.

Comparison of Alveolar pCO? and Alveolar Ventilation
Breathing Air, Before and After Acetazoleamide
One hour after 10 mg/kg of orally administered acet

azoleamide, there was no significant change (P>0.5) in
alveolar PCO2 from that of the control period (see Table II
-Air).

No significant change in either alveolar ventila

tion (P>0.3) or minute volune (P>0.4) was seen one hour
following this dose (see Table Ill-Air and Table IV-Air).
This is also illustrated in the mean air points described
by ’’air” in Figures 6 and 7, which represent a plot of the
mean alveolar pCC^'s vs. the mean minute volumes for both
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control and acetazoleamide-treated subjects.
are seen to be nearly identical.

These points

Red blood cell concentra

tions of acetazoleamide at this point ranged from 5-25
micrograms/cc (mean=12 micrograms/cc) .

These data indicate

no change in threshold of the organism to alveolar PCO2
stimulus when such moderate drug levels are achieved.
2.

Changes in Ventilation After Acetazoleamide
While Breathing 10% Oxygen Mixtures
This section deals with the characteristics of venti

lation while breathing a low oxygen mixture following mod
erate (10 mg/kg) oral doses of acetazoleamide.

In the five

subjects studied in this manner, alveolar ventilation dur
ing control periods did not appear significantly different
(P> 0.4) from that while breathing a 10% oxygen mixture
after this dosage.

Comparison of minute volumes during

both periods was also statistically insignificant (P^O.8).
In addition, there was no significant alteration in endtidal pC02 (P>0.9) after such administration, while breathing the low oxygen mixture.

These data are summarized in

Tables II, III, and IV-10% Oxygen, and in Figure 5.

There

appeared to be no constant relationship between red blood
cell drug concentrations and changes in ventilation among
these subjects.
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EFFECTS OF ACETAZOLEMUDE (10 Mg./Kg.) ON HUMANS
BREATHING 10$ OXYGEN
MEAN-5 SUBJECTS*
Control

Alveolar P COp
(Mm. Hg.;
Minute Volume
(L./Min. BTPS)
Alveolar Ventilation
(L./Min. BTPS)

Acetozoleainide

28.0

26.7

2U.0

27.8

10.8

13.5

* fi.'B.L. Levels 8-20 ug./cc.

I

1
Figure 5* Changes in Ventilation One Hour
After 10 mg/lcg Oral Acetazoleamide, While
Breathing a 10% Oxygen Mixture.
3.

Ventilatory Response to Inspired
Carbon Dioxide Mixtures
Eight subjects were successfully tested as to their

response to inspired mixtures of carbon dioxide following
10 mg/kg of oral acetazoleamide.
are tabulated in Tables II - V.

The results of this study
Each subject breathed

either 2% or 4% carbon dioxide in air or both.

These ex-

perimental periods were separated by rest periods of
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15 minutes and an equilibration period of five minutes in
both the control and experimental situations.
Increased sensitivity to inspired carbon dioxide, as
measured by the stimulus-response curve, i.e • # avre/apa
CO2
was seen in both the 2% and the 4% carbon dioxide-breathing
series (see Figures 6 and 7).

These responses represented

variable increments in frequency and/or tidal volume.
These changes are statistically significant in the case of
4% carbon dioxide (P>0.2), and to a greater extent, in the
case of 2% carbon dioxide breathing (P>0.1).

A similar

increase in sensitivity is seen when the slope of the re
sponse curve comparing change in alveolar ventilation
(AVRa) with change in alveolar pC02 is analyzed.
The usual increase in physiological dead space accompanying the hyperpnea of carbon dioxide inhalation. 100 was
seen in this series also, but without relation to the actual alveolar pC(>2# i.e •» the dead space while breathing
4% carbon dioxide was not significantly greater than that
breathing 2% carbon dioxide, though both were larger than
air-breathing controls.
In two subjects, mixed venous pCC^'s were determined.
The results are equivocal and the sample too small to infer
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any positive correlation between changes in mixed venous
pC02 and changes in alveolar or minute ventilation
(AVR/APv

vco2

).

Further studies in this direction are indi-

cated.
Analysis of red blood cells and plasma revealed con
centrations of acetazoleamide during the experimental car
bon dioxide-breathing periods ranging from 4.14-61.61
micrograras/cc in the erythrocyte and from 8.22-52.02 micrograms/cc in plasma.

There was no readily apparent dose-

response relationship.

Maximal concentrations of the drug

were seen to be reached in the red cell within approxi
mately 90 minutes after the oral administration of the
agent and were at their height during the carbon dioxide
breathing period.
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Figure 6, Effect of 10 mg/kg Oral Acetazoleamide on Sensitivity to 2% Carbon Dioxide in
Air (Inspired)*

Alveolar pC02
(mm Hg)
Subject

2%

Air

4%

C02

C02

10%
C

o2

C

D

C

D

C

D

D

1
2
3
4
5
6
7
8

35.2
36.1
39.7
39.6
33.6
41.2
35.5
29.8

35.2
37.1
39.4
40.2
32.8
37.3
35.9
41.5

36.5
37.1
41.1
41.2
36.4

35.8
36.1
40.1
40.6
37.0

38.2
40.7
45.7
44.8
42.4
43.5
38.6
44 • 9

37.1
41.6
43.5
43.0
40.5
39.4
37.5
44 • 3

17.2
30.0
32.7
28.6
31.5

15.8
30.8
30.6
28.2
28.1

MEAN

36.3

37.4

38.5

37.9

42.4

40.9

28.0

26.7

TABLE II

C « Control
D = After Acetazoleamide (Diamox) 10 mg/kg orally
U>

Minute Volume
(L/min DTPS)
Subject

Air

2%

4%

C02

C02

10%

o2

C

D

C

D

C

D

C

D

1
2
3
4
5
6
7
8

11.49
7.66
9.77
9.14
9.65
6.58
11.48
9.36

8.62
7.74
8.12
7.82
12.55
7.72
9.21
7.82

28 • 15
11.40
16.79
17.03
18.66

26.49

32.00
14.53
25.57
30.56
24.23
16.47
30.88
26.07

34.41
23.60
27.16
32.30
35.74
17.89
34.21
23.82

41.54
17.78
15.54
20.23
25.87

49.71
19.61
28.40
20.56
20.74

MEAN

9.39

8.70

18 • 41

21.65

25.04

28.64

23.99

27.80

19.44
17.61
23.05

TABLE III

*

Alveolar Ventilation
(L/rain BTPS)
Subject

2%

Air
C

D

4%

C02

C

D

1
2
3
4
5
6
7
8

8.49
4.65
5.51
5.30
6.28
3.91
8.74
5.92

5.39
4.19
4.54
4.99
7.53
3.85
5.59
3.54

13.37
6.49
10.60
9.75
12.04

15.52

MEAN

6.10

4.95

10.45

11.61

10.90
7.98
12.03

C

10%

C02

D

12.77
22.17
25.20
19.08
13.25
29.66
20.50

18.14
22.41
28.53
37.78
15.19
29.38
18.39

20.38

24.26

o2

C

D

16.54
8.03
8.97
12.11
8.16

28.87
7.82
8.52
8.47
13 • 83

10.76

13.51

TABLE IV

Ik
y*

Ratio of VRe to Change in Alveolar pC02 While Breathing Carbon Dioxide
(L/min/mm Hg)
Subject

2%

4%

C02

C

D

1
2
3
4
5
6
7
8

11.98

26.27

5.02
5.12
3.22

15.94
27.99
2.46

MEAN

6.34

18.17

TABLE V

C

CO2
D

6 • 84
1.49
2.65
4.18
1.67
4.23
6.36
1.11

13.22
3.50
4.67
8.71
2.98
4.80
1.53
4.92

3.57

5.54
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Figure 7, Effect of 10 mg/kg Oral Acetazoleamide Upon Sensitivity to 4% Inspired Carbon
Dioxide•
4.

Early Adjustments Following Oral
Acetazoleamide, Breathing Air
Continuous analysis of respiration was carried out in

three subjects during the hour-long “induction period" fol
lowing 10 mg/kg orally of acetazoleamide.
In these cases an initial hyperpnea was seen to exist.
followed by a return to control levels at hour's end.
is demonstrated in Table VI.

This

We cannot report on the basis
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of these data alone whether or not there has been, as is
suggested,an initial decrease in carbon dioxide output
relative to ventilation during this period.

Subject

1

2

3

Time

FA

CO 2

VE

(DiamoxR) RBC

0
429*
+ 38 ‘
+ 48 *
+ 60 1

.0565
.0495
.0440
.0430
.0560

9.77
19.04
17.37
13.45
8.12

8
12
15
23

0
+ ll1
+ 20*
+ 42 ‘
+ 60*

.0563
.0585
.0560
.0565
.0571

7.14
9.20
8.31
8.59
7.82

1
4
10

0
+ 20 ‘
+ 60*

.0600
.0555
.0565

10.32
14.28
11.36

0
6
16

Changes in Vehtilation During the
Table VI
Hour Following 10 mg/kg Oral Acetazoleamide,
Breathing Air.
In one subject in this first series, pH measurements
were performed on arterial blood drawn from an indwelling
Cournand needle.

This subject is not used elsewhere in

this paper because of obvious cortical control of ventilation on the test gas mixtures.

In this subject, a fall

in pH from 7.43 to 7.35 was seen during this hour-long

0
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Hinduction period*'.

At the end of this time the erythro

cytic concentration of acetazoleamide was only 4.0 micrograms/cc.

During the hour his alveolar ventilation had

fallen from 6.0 to 3.5 L/min, however, suggesting to us
that if indeed this was a true acidosis, it played an in
significant role in the stimulation of respiration on the
basis of this data.

In addition, it is significant to note

that this is the only subject in whom a decrease in pH was
seen at any time, even in the face of the much larger doses
of acetazoleamide used in the following section.

It is not

impossible that this change, and the pH changes reported
elsewhere, may be reflections of changes in the arterial
blood once it has been withdrawn from the artery.

This

possibility has been suggested by Cranston et. al
B.

Large Dosage (to 50 mg/kg) Intravenous Studies
1.

In the first subject, CRC, 50 mg/kg of parenteral

acetazoleamide was administered and ventilatory parameters
studied at rest and during exercise.

The results of this

experiment are tabulated in Table VII.
Considerable increase in resting minute and alveolar
ventilations (approximately 86%) was noted after a single
intravenous injection of this magnitude.

Concurrently,
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there was a decrease in carbon dioxide output of approxi
mately 10 per cent.

This decrease reflects a drop in alve

olar pC02 (by 13 to 16 ram Hg) and expired pC02 (not shown
in this table).
Arterial pC02 was not significantly changed after this
injection.

If anything, there was a decrease in arterial

pC02 over untreated resting controls.

The decrease in al

veolar pCC>2 and the relative normalcy of arterial p0O2 were
productive of A/a pCC>2 ratios of the small magnitude seen
in Table VII, following injection.
was seen in this series.

No fall in arterial pH

If anything, a small increase was

seen in this and succeeding subjects.
During exercise after acetazoleamide there was no sig
nificant increase in minute ventilation over the control
exercise period.

An increase in arterial pC02 was seen in

both control and experimental situations, however, over
resting levels, much greater in the latter.

The carbon di

oxide output after injection of the agent during exercise
was seen to be considerably less than the control exercise
values.

This was productive of a distinctly smaller (.690

vs. .916) R.Q. value in the treated case.

Smaller oxygen

consumption was noted in this situation as compared with

VERNIER PADCLIFFR MEMORIAL LIBRARY
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the nontreated state, also.
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The marked elevation in arte

rial pC02 seen here was accompanied by a distinct lowering
of the alveolar pC02# producing an A/a pCC>2 ratio for the
acetazoleamide-treated exercise state of .301.
2.

The effect of graded doses of acetazoleamide to

total 50 mg/kg in subject RMO is tabulated in Table VIII.
A hyperpnea roughly related to the total incurred dose was
observed in this experiment.

Decrease in the A/a pCC>2

ratio was again seen, related to a decrease in alveolar
The A/a pC02 ratio decrease was not seen to be as

pC02.

great as that with the single injection.

However, somewhat

lower erythrocytic levels of the drug were obtained.
3.

The effect of graded doses of acetazoleamide to

total 45 mg/kg is tabulated in Table IX.

Similar results

to that in subject RMO were seen in this subject, CB.
4.

The effects of single 50 mg/kg injections in sub-

jects GB and BA are tabulated in Tables X and XI.

One

notes the initial drop in R.Q. secondary to a decrease in
the carbon dioxide output in both these subjects and in
subject CRC, immediately after injection of the drug.

A

mild, transitory hyperpnea was also associated with this
phenomenon.
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In all the above experiments, resting control values
for the A/a pC02 ratio were approximately unity (1.022±
0.060).

In this series of five subjects, the A/a pC02 ra-

tios after large intravenous dosages were between 0.8-0.6
at rest.
exercise.

The ratio dropped still further, to 0.3, during
This decrease was related to a decrease in alve-

olar PCO2 in the face of relative normalcy of the arterial
PCO2•

An actual trace of two such experiments immediately

after administration of the drug in single injections is
seen in Figure 8.

The relationship of A/a PCO2 ratios to

erythrocytic acetazoleamide levels is seen in Figure 9, and
to plasma drug levels in Figure 10.

In Figure 9, these

data are contrasted with those which Collier21 obtained in
dogs.
The small size of this series, and the protocol dif
ferences among the members of this series, is in part ex
plained by the clinical symptoms produced by such large
doses of the drug (some 15-20 times the normal therapeutic
dosage).

These effects included transient hyperventila

tion, numbness and tingling of the extremities, incapaci
tating headache, drowsiness, disorientation, confusion, and
tinnitus.

Nausea and ‘'heartburn'* were less constant
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complaints.

These symptoms often extended into the day

following the experiment and, since the subjects were all
either students or teachers, these effects were deleterious
to both physical comfort and to the performance of neces
sary activities.
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Effects of Single 50 rag/kg Injection of Parenteral Acetazolearaide
in Subject CRC, 80 kg W.M.
Situation

Time

f

vT

VD

R

A/a

&] c K! P

pH

Vc°2

V0
u2

4.14

.223

.286 .780 37.3

36.0

19.96 1.984 .252 39.60 32.58

1.451

1.585 .915 36.6

37.0

.989

7.45
7.45

V

'£

PAC02 Pa

C02

Control
Rest I

.0

10.00

Exercise

-+ 2u

Rest II

4-35 1 11.62

Diamox

.825 .311

.780 .280

8.25

1.03

9.06

4.65

.229

.278 .825 35.1

36.1

.972

7.45

0

Rest III

+ 5* 10.85

.971 .235 10.53

6.90

.202

.296 .690 22.0

34.4

.640 167

273

7.50

Rest IV

•+15 * 11.44 1.062 .313 12.15

7.43

.213

.235 .906 21.7

35.3

.615 106

187

7.50

Rest V

+ 2 1 11.41 1.045 .326 11.93

7.06

.200

.221 .905 21.2

33.9

.625

88

168

7.48

Exercise

+35 * 18.57 2.209 .175 41.02 35.91

.625

.905 .690 13.5

44.8

.301

80

161

7.40

TABLE VII

ut

o

Effects of Graded Doses of Parenteral Acetazoleamide
in Subject RMO, 90.6 kg W.M.
Time

Dose

f

VT

¥D

VE

V CO

2

Vo

°2

R

CO 2 pa CO 2

A/a

LdJc [d] P

S'

pH

8.41

.978 .343 8.22 4.45 .243 .313 .777 39.4

40.1

.984

8.45

.994 .377 8.40 4.37 .248 .303 .818 41.2

39.3

1.048

10 mg/kg

7.55

1.143 .437 8.63 4.58 .249 .330 . 775 40.4

36.9

1.095

5

39

4- 70* 25 mg/kg

7.89

1.115 .337 8.80 5.35 .242 .273 .886 34.1

36.4

.937

32

119

7.43 .1720

40 mg/kg

7.43

1.212 • 467 9.01 4.79 .209 .237 .882 32.3

36.9

.875

53

141 ~

7.39 .1780

6.881 1.313 .400 9.04 5.60 .233 .297 .785 32.2

37.5

.859

55

155

7.39* .1710

0
+ 28 1
+ 50‘

+ 85’

+105* 50 mg/kg

7.43

.1650

7.43 .1670
7.43

.1650

'.!V

TABLE VIII

* Samples so marked were not analyzed
until one-half hour after withdrawal
ip
'•4

Effect of Graded Dose of Parenteral Acetazoleamide
in Subject CB, 65 kg W.M.
Time

Dose

f

VT

V

D

'.7

E

VA

V CO

v

2

02

R

PaC02 p a CO
2

A/a

Me Mp

pH

F

9.80

.659 .234 6.46 3.19 .190 .240 .792 39.4

38.9

1.013

7.42 .1660

+12'

8.81

.733 .235 6.45 3.51 .196 .251 .781 38.7

36.9

1.049

7.42 .1660

+35* 25 mg/kg

8.59

.745 .233 6.40 3.54 .178 .220 .809 35.2

37.6

.935

48

114

7.44 .1690

+60' 45 mg/kg

8.62

.883 .313 7.61 4.05 .187 .260 .719 33.0

37.7

.875

73

124

7.45 .1700

11.70

.731 .217 7.01 4.84 .217 .247 .879 31.2

36.2

.863

98

159

7.40 .1750

0

+82*

TABLE IX

‘V-

CD

Effects of Single 50 mg/kg Injection of Parenteral Acetazoleamide
Subject GB, 83 kg W.M.
Time
Control
I

4-

f

7.27

VT

VD

.878 .218

VE

VA

V CO

2

vO

R

+ 37’

7.02 1.192 .290
10.26

.697 .259

Pa

CO 2

A/a

Me MP

pH

6.39 4.07 .240 .274 .88 43.0

44.0

.977

23.0

36.2

.635 136

283

7.47

8.37 5.63 .218 .314 .69 29.46 37.3

.790 116

217

7.43

7.16 3.47 .165 .244 .68 31.6

37.6

.840

66

172

7.44

35.5

38.3

.927

58

111

7.42

2’

+ 12’

P

2

+ 70*

7.43

+ 100*

5.30 1.212 .459

6.42 3.46 .160 .209 .77 36.4

37.6

.945

55

71

7.41

*140'

6.67 1.510 .436 10.07 6.50 .245 .331 .74 29.5

30.6

.964

44

61

7.43

TABLE X
* Subjective symptoms were great here
in

\D

Effects of Single 50 mg/kg Injection of Parenteral Acetazoleamide
Subject BA,
Time

f

VT

VD

vE

*
VA

77 kg W.M.

Vco2 ^°2

R

P

^CO

P
2

aco2

A/a

[p]c [?]p

pH

Control
I

14.00

.657 .217

9.20 4.76 .268 .286

.94 37.63 37.60 1.00

7.38

II

14.34

.680 .275

9.75 4.37 .263 .257 1.02 39.41 38.30 1.03

7.35

12.09

.810 .075

9.80 7.68 .186 .309

DiamoK

+

5'

+ 25 *

.60 23.08 36.5

.632 157

313

7.40

29.68 37.6

.789

74

242

7.38

+ 35*

14.63

.863 .343 12.62 6.15 .262 .315

.83 29.82 37.7

.791

63

147

7.35

+ 55*

13.12

.968 .370 12.70 6.53 .305 .371

.82 33.73 38.7

.872

57

141

7.32

+*90*

22.0

.825 .361 18.16 8.01

.86 31.95 35.8

.893

54

124

7.33

34.08 39.7

.859

38

117

7.30

.91 26.98 30.2

.893

33

69

7.34

.376 .436

+130*
+150’

12.94 1.119 .397 14.48 8.05 .291 .318

TABLE XI

* Subjective symptoms were great here
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SUMMARY AND CONCLUSIONS
In evaluating the results of the foregoing experiments
it is important to recall two concepts dealing with the
area under study*

(1) The carbonic anhydrase-catalyzed

carriage system is not the sole agent responsible for car
bon dioxide transport as evidenced at the lung.

Thus, one

searches for indications of qualitative as well as quanti
tative changes in the system when one part of it is inhibited.

(2) As is true of all enzyme systems, inhibition of

carbonic anhydrase is achieved only when adequate inhibitor
levels are reached.

In a system in which other carriage

forms exist, changes due to "partial inhibition" will of
consequence be subtle, and the effects of total inhibition
might not be as dramatic as if the integrity of the whole
transport mechanism were dependent upon the enzyme.
These observations concerning the effects of smalldosage acetazoleamide administration on resting ventilation
Q

are in support of those of Becker et aly in that no sig
nificant changes in minute volume or alveolar pC02 could be
attained at red blood cell drug concentrations ranging from
5 to 25 raicrograms/cc.

On the basis that such low concen

trations of the inhibitor did not appreciably lower the A/a
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PCO2 ratio (see following), it is inferred that there is no
significant change in threshold to either alveolar or arte
rial pCC>2 stimulus to respiration at these drug levels in
the normal individual.
In three subjects in which the "induction period" fol
lowing 10 mg/kg of acetazoleamide was monitored, however,
an early hyperpnea was seen to exist, followed by a return
to normal control levels at hour's end.

This hyperpnea was

associated with a simultaneous decrease in end-tidal pCC>2 •
Unfortunately, the data on expired carbon dioxide and
oxygen concentrations is not accurate enough to allow as
critical an evaluation of this period as others61'67 have
done in dogs.

At face value, these data are at variance

with those of Tomashefski et al. 104 who showed a decrease
rather than a rise in minute ventilation at slightly higher
doses in animals.

Evaluation of the more complete data in

the section dealing with higher doses seems in support of
the concept of Mithoefer67 that there is an early decrease
in carbon dioxide output relative to ventilation when carbonic anhydrase is inhibited.

In the high-dosage studies.

an immediate significant hyperpnea is seen following intra
venous administration of the drug.

Simultaneously, carbon
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dioxide output and the respiratory quotient are seen to
drop.

The time in which these changes occur precedes by

some time (see Maren et ai57) the renal effects of the
drug.
The nature of the low dosage ventilation and renal
changes are such that one must seek reasons for the obvious
inequality in sensitivity of the respiratory (erythrocytic)
and renal (tubular cell) carbonic anhydrase-catalyzed and
influenced mechanisms.

It will be recalled that the effec

tive therapeutic (diuretic) dosage of acetazoleamide is
less than 5 mg/kg, only one-half the low-level dosage used
here.

We have mentioned the problems of "degree-vs.-kind'*

earlier in this section, and it is here that this discussion is particularly apropos *

It will be recalled that

carbonic anhydrase is the chief agent responsible for tubular bicarbonate reabsorption. 12, 39

Thus, when this mecha-

nism is depressed, no other ready mechanism for bicarbonate
reabsorption exists, and the characteristic alkaline diuresis produced by acetazoleamide occurs.

Small decrements in

enzyme activity at this site may be all that is necessary
to produce this diuresis.
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On the other hand, the effects of "partial inhibition”
of carbonic anhydrase are less well felt in the carbon di
oxide carriage system in the blood.

Carbon dioxide, when

carried in such an aqueous solution, assumes many forms:
dissolved molecular carbon dioxide as it is produced at the
tissues and excreted at the lungs; carbonic acid; bicarbon
ate ion; carbonate ion; and carbamates.

These forms exist

in a "mobile equilibrium >•31 with each other, and the reac
tions of interconversion are rapid indeed (see Figure 1).
This latter group of compounds, the so-called "carbamino”
compounds, are highly important in this system.

The forma

tion of carbamates from amines and carbon dioxide is ex
tremely rapid and requires no catalyst.31'35'^6
Ferguson and Houghton35 estimated that under physio
logical conditions, about 1 millimole of carbon dioxide/
liter of red blood cells was carried as carbamate in arte
rial blood, and about 1.6 millimoles/liter of red cells in
venous blood.

Ferguson calculated that in man at rest.

carbamino-bound carbon dioxide was responsible for about
30 per cent of the total changes in whole blood carbon di
oxide tension during the respiratory cycle and for as much
as 75 per cent of the changes in the red blood cells them
selves.
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Cain et al,^ as recently as 1959, has partitioned the
carbon dioxide output due to dissolved, carbamino-bound.
and bicarbonate carbon dioxide in pumped, anesthetized dogs
(see Figure 11).

Using the data of Ferguson and Rough-

ton,34 he assigned 17 per cent of the output to dissolved
carbon dioxide, 25 per cent to the carbamino-form, and 58
per cent to bicarbonate.

Meldrum and Houghton62 postulated

that when the carbonic anhydrase system was inhibited, much
of the carried carbon dioxide had properties resembling
that of the carbamino compounds described above,

This was

supported by the recent work of Cain e_t al’*-6 (see Figure 11
below) .

That the body possesses more than one available

"cushion" for the effects of carbonic anhydrase inhibition
is indicated by the data below.
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Cain, Stainsby and Otis

Figure 11. Partition of the Carriage Forms of
Carbon Dioxide Before and After Acetazoleamide
in Dogs. From Cain et al."^
The effects of such inhibition were accentuated in the
case of the solitary experiment in which exercise was per
formed (see Table VII, exercise).

From this data, it is

postulated that the speed of the alternate carriage mecha
nisms described above is not adequate to compensate for the
increased rate of blood flow past the functioning alveolar
capillary junction and the increased carbon dioxide produc
tion by the more actively metabolizing organism during

67
exercise.

This is in support of the earlier work of

others.®^' ^3.
Our 10% oxygen-breathing experiments with small doses
of acetazoleamide were not productive of a new use for the
drug in altitude acclimatization.

The reader will recall

the work of Carter and Clark18 (see Table I) in animals, in
which they indicated that such might be possible.

Similar

changes could not be achieved using small (10 mg/kg) doses
in humans at rest (the present work) or at exercise (C. R.
Collier - unpublished observations).

However, considera

tion of Carter and Clark's data reveals a decrease in the
A/a ratio from control levels of 0.77 to 0.43 in the
treated state.

This possibly resulted in a favorable situ-

ation for the organism at such "altitudes".

A1though arte-

rial gas tensions were not measured in this portion of the
research, one would not expect any decrease in the A/a pCC>2
ratio at the drug levels (only 8-20 micrograms/cc) which
were attained while breathing 10% oxygen.

The toxic ef

fects of the agent at levels to produce A/a pC02 ratios in
the neighborhood of 0.5 are too great to suppose that such
a use is feasible.
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We were able to confirm the work of Cranston et al^
and Stapleton^1® who were not able to demonstrate any sig
nificant increase in ventilation following 25 mg/kg of
acetazoleamide in response to 3-6% mixtures of inspired
carbon dioxide.

Breathing 2-4% carbon dioxide mixtures.

there were no statistically significant differences between
control and experimental states (10 mg/kg) in minute vol
ume, alveolar ventilation, or alveolar pC02 (Tables II-IV).
However, the ratio of minute volume change to change in al
veolar pCC>2 does increase significantly after such a dose
(see Figures 6 and 7),

The slope of such a curve has been

considered by others^'to be an index of "sensitivity'* of the organism to carbon dioxide.

Locke et al^ had

noted such an increased "sensitivity" following sulfanila
mide administration.
The meaning of these data is not readily apparent.
Eldridge and Davis32 have pointed out in a related paper
that the ventilatory response to carbon dioxide varies with
the mechanical properties of the system, properties which
are, of course, abnormal in the face of pulmonary disease.
A similar problem arises in the face of acetazoleamide
therapy, where the aberrations are biochemical, rather than
mechanical ones.
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The first, and regretably one of the hardest to answer
questions at this point involves the pCC>2 that the respira
tory center sees as its stimulus to action following acetazoleamide*

Possibilities are, of course, (1) the pC02 of

the respiratory center per se, (2) the pC02 of the venous
blood draining the center, (3) the pC02 of mixed venous
blood, and (4) the pCC>2 of the arterial blood perfusing the
center.
It has been shown by several workers5'^ that carbonic
anhydrase is present in both the gray and white matter of
bloodless brain tissues.

The exact function of the enzyme

in this location is not clear.

Ashby and her coworkers6

have suggested that the enzyme is concerned with cerebral
dominance and integrative functions in primates.

It is

well known that tissue hypercapnia, like hypoxia, will spe
cifically inhibit the speed of nerve conduction and depress
the nerve's sensitivity to stimuli, and it is suggested
that carbonic anhydrase may function to anchor carbon di
oxide as bicarbonate in the peri-neuronal cells, thus in
creasing the pC02 gradient away from the firing neurones.
That this is the case has also been suggested by Oechslin
and Nichols.6^

If this were true, however, one would have
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to postulate that carbon dioxide could enter the blood
stream as bicarbonate, a concept not in keeping with pres
ent thought on this subject.
Alternatively, the enzyme may produce pH optima of
benefit to other enzymes or enzyme systems functioning in
the chain of reactions associated with healthy brain me
tabolism.

Findley (unpublished observations) has recently

demonstrated a high tissue pC02 in dog brains following
acetazoleamide administration.
Several workers8'20'23 feel that in the 5-12% carbon
dioxide range, the effect of the respiratory stimulus is
due to the action of carbon dioxide (as the molecular gas
and not as carbonic acid or bicarbonate) upon the respiratory center itself.

However, this concept is greatly dis-

puted and the field remains relatively untouched as far as
significant research is concerned.
Little is known regarding the effects of arterial PCO2
and bicarbonate on the respiratory response to carbon di
oxide after acetazoleamide.

Most of the evidence in this

field is of an indirect nature.
Cranston et al,2^ whose work is referred to earlier.
felt that probably the arterial rather than the tissue PCO2

71
that was related more closely to the control of respiration
following acetazoleamide.

An inconstant lowering of the

arterial PCO2 secondary to an increase in alveolar ventila
tion has been seen repeatedly following acetazoleamide
therapy in patients suffering from chronic respiratory
acidosis.3*1'

101,102

Other workers, among them nota

bly Platts et al,73 admit only to a fall in the plasma bi
carbonate concentration in consequence of the usual bicar
bonate diuresis which the drug induces.

Gray37 has shown

that a decrease in arterial pH secondary to a fall in
plasma bicarbonate concentration is a poor respiratory
stimulant indeed and Barak et al, 7 noting that ammonium
chloride administration produced a similar fall in arterial
PCO2 but not subjective improvement in such patients, at
tributed the beneficial effects of acetazoleamide to a
“still unknown effect’1 of the drug.
One explanation offered for this apparent decrease in
arterial PCO2 in such patients is that a resensitization to
carbon dioxide as a respiratory stimulant has been achieved.
This mechanism has been suggested by several authors. 12,112
Others, 76,102 however, disagree, feeling that the normal
increase in buffer base commonly seen in chronic acidotics
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would tend to minimize the sensitivity of the organism to
carbon dioxide.
It has been well documented^ that patients with severe
cor pulmonale and emphysema demonstrate a lower than normal
response to carbon dioxide inhalation.

Several work-

ers36'1^0 have been able to show that after moderate
(10 mg/kg/day) acetazoleamide therapy, a decrease in the
threshold of the respiratory center to carbon dioxide
seemed to occur.

Ventilation is greater than in control

emphysema patients, in spite of lower arterial peek's.
This change in threshold seems in direct response to the
initial untreated arterial pC02# and not to an increased
blood bicarbonate content.
body of data, i.e

• 1

Tenney 102 feels that this whole

that obtained in emphysematous pa-

tients, is not a good indication of the action of the drug
on either internal or external respiration for both bio
chemical and mechanical reasons, most of which seem valid.
(Also see Eldridge and Davis32 in this respect.)
In closing this discussion, reference is made to the
work of Rahn and Otis75 and of Kellogg,48 who studied the
respiratory response to carbon dioxide after acclimatization to altitude in man.

In at least the acute stage, the
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hyperpnea caused by hypoxia is productive of an increase in
serum bicarbonate and a fall in alveolar pCC>2.

The accli

matized person, on the other hand, has a decreased buffer
ing capacity of blood and tissues due to excretion of bi
carbonate base.

He possesses a greater minute ventilation

and consequently a still lower pC02 and a higher pC>2 than
the unacclimatized person when both are exposed acutely for
one hour to the same altitude.

In this state, a greater

response for any given inspired carbon dioxide tension was
seen.

It will be recalled that Carter and Clark1® were

able to mimic this effect by the use of acetazoleamide, and
we have suggested that at higher doses a similar effect
could be attained in man.
The complete answer to this problem has by no means
been determined.

Definitive studies are needed in unanes

thetized experimental animals in which changes in arterial
(carotid), venous (jugular), and brain tissue peek's are
simultaneously monitored following acetazoleamide in re
sponse to carbon dioxide inhalation.
In terms of positive results, our studies with large
intravenous dosages were more rewarding.

It was possible

to demonstrate that, with drug levels roughly twice that
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required in pumped, anesthetized animals,21 a similar de
crease in the alveolar/arterial (A/a) pC02 ratio could be
achieved.

This effect could be heightened during exercise,

a fact which supports the earlier work of Houghton et al87
and Shepard,^1 who used lower dosages of the agent.

The

reason for differences in canine and human experiments us
ing similar doses of the agent may lie in the recent in
vitro observations of Collier (unpublished data), who
showed that canine erythrocytic carbonic anhydrase was con
siderably more susceptible to acetazoleamide-induced inhib
ition than was enzyme obtained from human erythrocytes.
(See Figure 12)

Qualitative, as well as quantitative dif

ferences in the two species may yet be described.

Maren

(personal communication) has data which suggests that there
may be species differences in plasma and red cell binding
capacities for the drug.
The early changes in ventilation at rest which oc
curred following a single large intravenous injection were
interpreted to indicate a temporary embarrassment in carbon
dioxide excretion at the lung.

With this degree of inhibi-

tion of the enzyme (probably greater than 90 per cent) the
alternate carriage mechanisms we have referred to earlier
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were probably unable to handle carbon dioxide output in a
normal manner.

Later, as excretion of the drug progressed

and the renal effects of the agent were probably felt.
trans-alveolar carbon dioxide excretion was again able to
proceed in a normal manner, although the A/a ratio was
still depressed.
In summary, this research was productive of the fol
lowing items of experimental evidence:
1,

At therapeutic dosage levels, no apparent ventila

tory changes are seen in humans, with the possible excep
tion of a transient hyperpnea.
2.

The low dosage effects of the drug are such that

it probably has no use in the development of rapid, artifi
cial acclimatization to high altitudes.
3.

When there is any strain placed upon the alterna-

tive carbon dioxide carriage mechanisms, e.g • $ during exercise or carbon dioxide inhalation, changes in ventilation
occur over nontreated controls.

Though the mechanisms

whereby these changes occur are obscure, it is probable
that the organism exhibits a greater sensitivity to carbon
dioxide tensions in the treated state.
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4.

At doses in the neighborhood of 50 mg/kg, definite

and marked decreases in trans-alveolar carbon dioxide ex
cretion could be measured.

A decrease in the end-tidal

pCC>2 associated with a normal arterial pC02 is taken as
prima facie evidence for this concept.
5.

The failure of previous investigators to produce

marked alterations in ventilation in humans at rest was
probably due to failure to achieve adequate drug concentra
tion levels in their subjects and to correlate this data
with their experimental results.

Also, qualitative differ

ences in human and canine carbonic anhydrase as respects
acetazoleamide-induced inhibition may be responsible for
some of the discrepancies in human and canine experiments.
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Figure 12• Effect of Acetazoleamide on Inhibition of Human and Canine Carbonic Anhydrase
in Vitro,
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APPENDIX
VOLUMES; Timed volumes are indicated as V, non-timed volumes as V.
VE = Expired minute volume of ventilation, cc/min.
VA = Alveolar minute volume, cc/min.
VT = Tidal volume, cc/breath.
VD = Dead space volume, cc. Subscript indicates com
partment being measured, e.g., personal (pers.),
apparatus (app.), or analyzer (anal.).

V°2

= Oxygen consumption, cc/min.

^C02::: Car^on dioxide output, cc/min.
EXPERIMENTAL CONDITIONS: Gas volumes are always expressed
with a subscript denoting the conditions under which
they were measured, thus:
ATPS = ambient temperature, barometric pressure, satu
rated with water.
BTPS = body temperature (37° C), ambient barometric
pressure, saturated with water.
STPD = standard temperature (0° c), standard baromet
ric pressure (760 ram Hg), dry.
PRESSURES: Each molecule of gas in a system exerts a spe
cific pressure in that system, which is a function of
its fractional concentration therein, by the relation
ship:
(1)
EX = FX
- 47>
pX

= Partial pressure of any gas, X, in mm Hg.
= Barometric pressure, in mm Hg.

?H20t = £>art:*-a^ Pressure exerted by water vapor at
temperature t, degrees C.
89

90

FRACTIONAL CONCENTRATIONSs
Fj£ = Fractional concentration of any gas in a system.

OTHER QUANTITIESs
f

= Frequency of respiration, breaths/min.

R.G. = Respiratory quotient =
or R.
VRA

VG

2

= Ventilatory ratio determined by the relation
ship s
V
A
experimental
VA

vre

^C02

control

= Ventilatory ratio determined by the relation
ship:
*
VE

experimental
control

A Method for the Determination of Diamox
in Red Blood Cells and Plasma
The method used in this study is essentially that of
Maren et al^ who had modified the changing pH method of
Philpot and Philpot. 72

The principle of this method is

that acetazoleamide inhibits the hydration of carbon di
oxide when the gas is bubbled at a constant rate through
water containing an indicator dye which changes color at

91
around pH 7*0

In the uncatalyzed reaction, the time re

quired for hydration to occur is observed visually and re
corded by a stopwatch, as the carbonic acid formed neutral
izes a buffer base which has been added, and then returns
the indicator to its original acid color.

After the addi

tion of buffer and under the conditions later described.
about 58-65 seconds is required for this hydration to take
place in the absence of carbonic anhydrase.
In the catalyzed reaction, when carbonic anhydrase is
added the reaction rate increases and reduces the time re
quired for hydration by more than 50 per cent.

There is a

reproducible relationship between time and enzyme concen
tration.
In the inhibited reaction, addition of a known amount
of biological sample (containing an unknown quantity of
acetazoleamide) prolongs the reaction time in a fashion di
rectly proportional to the amount of inhibitor present.
Carbonic anhydrase in the form of heparinized dog
blood diluted Is350 in double distilled water is used
throughout (except in the uncatalyzed reaction).

1.0 ml of

this solution is roughly equivalent to two enzyme units if
0.5 ml gives a reaction time equal to one-half that of the

S2
uncatalyzed reaction.

This solution, unlike the others, is

relatively unstable and should be kept no longer than one
week at 4° C.
The indicator solution used in these studies is ob
tained by adding 2 5.0 mg of phenol-red to 1.0 I* of 0.0026 M
sodium bicarbonate.

3.0 ml of indicator are used in each

of the several types of determinations.
The buffer solution, of which 1.0 ml is used in each
determination, is prepared by adding 300 ml of 1.0 M sodium
carbonate to 206 ml of 1.0 M sodium bicarbonate, then di
luting to 1.0 Lwith double distilled water.
A stock solution of acetazoleamide to be used in con
structing the standardization curve is prepared by dissolv
ing 27.5 mg of Diamox^ sodium in 1.0 L of double distilled
water.

This solution has a concentration of 25 micrograrns/

ml and is stable for at least a month.

A working standard

of this solution is made by diluting the stock solution
1:250.
All solutions and the reaction chamber are kept in
crushed ice throughout the determinations, and the reagents
are stored under refrigeration when not in use.
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The biological material (cells or plasma) is diluted
Is100 and placed in a water bath at 100° C for 5 minutes.
This procedure destroys any carbonic anhydrase present
without effecting the inhibitor.

Sufficient sample is used

to prolong the reaction time 6-12 seconds in excess of the
catalyzed reaction, e.g * I from 26-32 seconds after the addition of buffer solution.

Smaller samples minimize foam

ing in the reaction chamber, a real problem at high protein
concentrations.

This method is much more accurate with

clear biological samples such as cerebrospinal fluid.
plasma, and aqueous humor.

For this reason, the red cell

suspensions are customarily centrifuged after boiling, and
the clear supernatant used for analysis.
The first procedure involves the determination of the
uncatalyzed reaction time.

Reagents are pipetted into the

reaction chamber in the sequence and amounts seen in
Table XII (line A).

The whole procedure is performed ra-

pidly with no delay between any of the steps.

1.0 ml of

buffer is added rapidly (we have employed a tuberculin
syringe for this purpose) and simultaneously the stopwatch
is started.

Time is recorded until the solution turns from

a red color to that in a comparator tube.

This tube is
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prepared by diluting 3.0 ml of the indicator solution to
7.0 ml with double distilled water and adjusting the pH to
the orange endpoint between red and yellow with acid.
After this procedure, the reaction chamber is evacuated
with suction and rinsed with double distilled water.

It is

desirable to reproduce each maneuver as closely as possible
on each run so that personal error is reduced.

Toward this

end also, three runs of each determination are made and the
average time is recorded.
permitted.

Deviations of -0.5 seconds are

Multiple determinations are made in all cases

(A-D in Table XII)*
Determination of the uncatalyzed reaction time is an
important check on the integrity of the indicator and buf
fer solutions, the rate of carbon dioxide flow, and the
purity of the double distilled water that is used.

This

procedure must be performed at the beginning and preferably
at the end of each day's work.

As has been mentioned ear

lier, 58-65 seconds is required for the uncatalyzed hydration reaction.

This range may be achieved by adjustment of

the carbon dioxide flow rate.
The procedure in the case of the catalyzed reaction is
essentially the same except for the addition of 1.0 ml of

Reactants Used in Various Portions of Acetazoleamide Determinations
in Biological Samples, All Quantities are in Milliliters
Indicator

Enzyme

A.

Uncatalyzed
reaction

3.0

B.

Catalyzed
reaction

3.0

1.0

C.

Diamox Stand
ard curve

3.0

1.0

D.

Unknown

3.0

1.0

Diamox
Solution

Unknown

0.2,0.4
0.6

0.1-2.0

2 D
Water

Buffer

3.0

1.0

2.0

1.0

1.8,1.6
1.4

1.0

1.9-0.0

1.0

TABLE XII

VO

S6
1:350 dog blood after the phenol-red and 2,0 ml of water
instead of 3.0 ml.

If foaming becomes a problem, the car

bon dioxide is turned off by means of a foot valve during
this period and turned on again immediately preceding the
addition of buffer.

Reaction times on the order of 20

seconds, i.e • t one-half that of the uncatalyzed reaction.
should be obtained.

This procedure serves as a check on

the enzyme preparation and as a further check on the purity
of the other solutions.

This determination is also run in

triplicate, and an average taken.
The Acetazoleamide Standard Curve is obtained by fol
lowing the same procedure as the catalyzed reaction, with
the addition of increasing amounts of acetazoleamide stand
ard solution immediately following the enzyme (see Table
XII, line C).

Water is added to make a total volume of

7.0 ml in each determination.

Three runs are made at each

concentration of inhibitor, and the Standard Curve is es
tablished for the day.

This curve must be established at

least once a day, and periodic checks with known amounts of
inhibitor are indicated for careful work.

A relatively

straight line in the Standard Curve indicates the absence
of impurities.

Slight lag at low inhibitor concentrations.
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i.e • # 0.02-0.04 micrograms, have been noted occasionally in
our hands.
The biological sample is assayed similarly, with the
substitution of the unknown for the standard solution in
this case.

From 0.1-2.0 ml of the unknown solution is

needed to place the inhibited reaction time on the high end
of the standard curve, where accuracy is greatest,

water

is added in every case to adjust the final vo3.ume to 7.0
ml.

The discretion of the operator determines when foaming

becomes an overwhelming problem and smaller amounts of sampie must be used.

When the amount of sample which will

cause the reaction time to fall on the appropriate part of
the standard curve is known, again three determinations are
made at that concentration of sample to determine the aver
age reaction time.
Calculations for the amount of Diamox in the sample
are simply performed:

'

uq Diamox/cc = /g/?c from standard, curve x 101
'
ml of sample used
(«g = micrograras)

(2)
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Reliability of Method
In Karen's hands no interference with this method was
found in normal biological tissues from rat and dog.
false positives were found.

No

A major potential source of

interference, tissue or blood carbonic anhydrase, is en
tirely destroyed by the heating of the sample and scrupu
lous cleanliness of all the glassware used.

Acetasole-

amide, on the other hand, is stable in both heat and cold,
and does not deteriorate with boiling or refrigeration.
Karen showed that repeated assays over the course of
several weeks showed no significant change in concentration
in iced and stored samples.

Blood from untreated animals

gave consistently negative results in assay for the drug.
The standard deviation of a single determination is approx
imately ilQ%.

For this reason, three determinations are

run in sequence for each biological sample and the time of
hydration is averaged.
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Previous studies dealing with the effects of oral
acetazoleamide (DiamoxR) administration in humans have
yielded equivocal results.

Effects of intravenous admin

istration of this agent, a potent carbonic anhydrase in
hibitor, have not been studied until recently.

It is

postulated that difficulty in interpreting these results
has risen in part from failure to evaluate given parameters
in terms of drug concentrations or degree of carbonic anhy
drase inhibition achieved.
These concentrations were ascertained throughout the
present work of this Thesis, which deals with the effects
of both small and large doses of this agent upon ventila
tory parameters in man.
In these studies, normal fasting young males were
first studied after an oral dose of 10 mg/kg using standard
techniques of spirometry and gas analysis.

No differences

in minute volume, end-tidal (alveolar) pCC>2/ or other ven
tilatory parameters were observed one hour after the drug
was administered, while breathing room air or 10% oxygen at
rest.

However, an increased ventilatory response to 2 and

4% carbon dioxide in air was observed after oral adminis
tration of this dose.
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After a sufficiently large (35-50 mg/kg) intravenous
dose, a concentration-related decrease in the alveolararterial (A/a) pC02 ratio similar to that earlier observed
in dogs was observed.

Blood gas determinations were car

ried out using suitable electrodes.

The A/a pC02 ratios

after this dosage were between 0.8-0.6 at rest (normal*!.0)
and dropped to 0.3 during exercise.

This decrease was

effected at a red cell concentration of from 60-80 micro
grams/ml, considerably greater than that necessary to
achieve similar results in dogs.

This decrease in A/a pC02

ratio was associated with a transient hyperpnea and a fall
in respiratory quotient secondary to a decrease in carbon
dioxide output.
These data are interpreted as indicating a definite.
dose-related effect of acetazoleamide upon carbon dioxide
output and ventilation in humans.

The acute effects of the

drug occur prior to the renal diuresis of bicarbonate, and
are consistent with the development of an impediment to
carbon dioxide transport across the alveolar-capillary
junction in the lung.

These effects are maximal when the

transport time of the blood through the lung is shortened
and the metabolic production of carbon dioxide is increased.
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as is the case during exercise.

In this case, the speed of

the alternate carriage mechanisms (primarily carbaminobound carbon dioxide) are probably not adequate to handle
the increased demands placed upon the carriage system.
These studies indicate that at dosage levels which can
be tolerated by humans the drug probably has no use in pro
ducing a rapid, artificial acclimatization to high altitude.
Recent in vitro studies have indicated quantitative
differences between canine and human erythrocytic carbonic
anhydrase.

These differences probably account for the dis-

crepancies which have existed in data obtained from such
subjects.
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